Schedule 13D ownership disclosure

CASI PHARMACEUTICALS INC

Ordinary Shares, par value US$0.0001 per share · CUSIP: G1933S101

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • SPARKLE BYTE LTDReported CIK 0001663831

    Shares: 1,019,852 · Class: 5%

  • SNOW MOON LTDReported CIK 0001663833

    Shares: 1,019,852 · Class: 5%

  • TIANJIN JINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP)Reported CIK 0001664019

    Shares: 1,019,852 · Class: 5%

  • Beijing Hexie Kangjian Investment Center (Limited Partnership)

    Shares: 1,019,852 · Class: 5%

  • Beijing Hexie Tiancheng Investment Management Center (Limited Partnership)

    Shares: 1,019,852 · Class: 5%

  • He Xie Ai Qi Investment Management (Beijing) Co., Ltd.

    Shares: 1,019,852 · Class: 5%

  • Xizang Hexie Enterprise Management Co., Ltd.

    Shares: 1,019,851 · Class: 5%

  • Zhuhai Hexie Zhiyuan Management Consulting Co., Ltd.

    Shares: 1,019,852 · Class: 5%

  • Jianguang Li

    Shares: 1,019,852 · Class: 5%

  • Dongliang Lin

    Shares: 1,019,852 · Class: 5%

  • Jingbo Wang

    Shares: 1,019,852 · Class: 5%

  • Kuiguang Niu

    Shares: 1,019,852 · Class: 5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000929638-26-000184
Form type
SCHEDULE 13D/A
Filer
CASI Pharmaceuticals, Inc.
CIK
CIK 1962738
Filed
Jan 20, 2026
Reporting period
Sep 30, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub